NASDAQ:YARW

Yarrow Bioscience Q1 2026 Earnings Results & Report

Yarrow Bioscience logo
$14.35 +0.00 (+0.03%)
As of 11:12 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Yarrow Bioscience beat analyst earnings expectations but missed on revenue in its Q1 2026 results, released May 15, 2026. The company reported EPS of -$4.00 versus the -$9.00 consensus estimate, while revenue of $86 thousand fell short of the $200 thousand estimate by $114.00 thousand.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Yarrow Bioscience EPS Results

Actual EPS
-$4.00
Consensus EPS
-$9.00
Beat/Miss
Beat by +$5.00
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Yarrow Bioscience Revenue Results

Actual Revenue
$86 thousand
Expected Revenue
$200 thousand
Beat/Miss
Missed by -$114.00 thousand
YoY Revenue Growth
N/A

Earnings Documents

Yarrow Bioscience Q1 2026 Earnings FAQ

Yarrow Bioscience (NASDAQ:YARW) reported earnings of -$4.00 per share for Q1 2026, beating the consensus estimate of -$9.00. The report was announced on Friday, May 15, 2026.

Yarrow Bioscience reported revenue of $86 thousand for Q1 2026, against a consensus estimate of $200 thousand.

Yarrow Bioscience Earnings Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
See More Yarrow Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Yarrow Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Yarrow Bioscience and other key companies, straight to your email.

About Yarrow Bioscience

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

View Yarrow Bioscience Profile